Nascent Announces the Completion of Its Phase 1 Clinical Trials
NORTH PALM BEACH, FL / ACCESSWIRE / February 28, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]
NBIO Fits Profile for Strategy Targeting Early Stage Biotech
One candidate that checks all of these boxes is Nascent Biotech Inc. (OTCMKTS:NBIO). NBIO checks all the boxes discussed above. It’s a dirt-cheap stock, trading on a market cap of just $16 [...]
Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board
VERO BEACH, FL / ACCESSWIRE / December 20, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]
Nascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394
VERO BEACH, FL / ACCESSWIRE / November 1, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]
Nascent Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical Research
VERO BEACH, FL / ACCESSWIRE / October 4, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]
Nascent Biotech Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
VERO BEACH, FL / ACCESSWIRE / September 13, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]
Nascent Biotech Inc (OTCMKTS: NBIO) Steady Rise Northbound as Phase 1 Clinical Trials Progress for Pritumumab (PTB) Targeting Glioblastoma
Nascent Biotech Inc (OTCMKTS: NBIO) is making a steady run northbound off its base at a nickel and saw some of its biggest gains while the overall markets saw steep declines. NBIO is a low float [...]
Nascent Biotech’s CEO Sean Carrick Featured in In-Depth Interview with Proactive Investors
VERO BEACH, FL / ACCESSWIRE / May 4, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage biotechnology [...]
Nascent Biotech Receives $750k Milestone Payment from BioRay Pharmaceutical
Milestone Payment is the Second of Four in $5M Pritumumab Licensing Deal February 23, 2022, 8:00 am EDT Dateline: Vero Beach Fl, USA Public Company Information: OTCQB: NBIO Vero Beach, Fl USA. – [...]
Nascent Successfully Completes 2nd Cohort Dosing in Key Phase 1 Metastatic Brain Cancer Trial
VERO BEACH, FL / ACCESSWIRE / January 11, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]